Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial (Q38391922)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 May 2016

Language	Label	Description	Also known as
English	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial	scientific article published on 12 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

1 October 2017

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

1 October 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Saby George

1

1 reference

Europe PubMed Central

1 October 2017

Robert J Motzer

2

1 reference

Europe PubMed Central

1 October 2017

Hans J Hammers

3

1 reference

Europe PubMed Central

1 October 2017

Bruce G Redman

4

1 reference

Europe PubMed Central

1 October 2017

Timothy M Kuzel

5

1 reference

Europe PubMed Central

1 October 2017

Scott S Tykodi

6

1 reference

Europe PubMed Central

1 October 2017

Elizabeth R Plimack

7

1 reference

Europe PubMed Central

1 October 2017

Joel Jiang

8

1 reference

Europe PubMed Central

1 October 2017

Ian M Waxman

9

1 reference

Europe PubMed Central

1 October 2017

Brian I Rini

10

1 reference

Europe PubMed Central

1 October 2017

publication date

12 May 2016

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

2

1 reference

Europe PubMed Central

1 October 2017

9

1 reference

Europe PubMed Central

1 October 2017

1179-1186

1 reference

Europe PubMed Central

1 October 2017

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Pseudoprogression and Immune-Related Response in Solid Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Molecular mechanisms of T-cell tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Improved endpoints for cancer immunotherapy trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Assessing oncologic benefit in clinical trials of immunotherapy agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

23 June 2018

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

31 August 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568541

31 August 2018

NCCN clinical practice guidelines in oncology: kidney cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27243803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAONCOL.2016.0775

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38391922&oldid=1757329813"